107.15 +0.24 (0.22%)
Pre-market: 7:25AM EDT
|Bid||107.08 x 1000|
|Ask||108.24 x 1000|
|Day's range||106.74 - 109.70|
|52-week range||81.66 - 109.70|
|Beta (3Y monthly)||0.55|
|PE ratio (TTM)||31.35|
|Earnings date||19 Nov 2019|
|Forward dividend & yield||2.16 (2.07%)|
|1y target est||107.26|
Financial shares led U.S. stocks lower on Tuesday to end a three-day rally as investors awaited comments from Federal Reserve Chair Jerome Powell at the end of the week. The S&P 500 financial index dropped 1.4% and the group weighed most heavily on the benchmark index among its major sectors, which all registered losses. The S&P 500 is now 4.1% shy of its record closing high in July after having fallen as much as 6.2% below that level.
Medtronic (MDT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Medtronic (MDT) delivered earnings and revenue surprises of 6.78% and 1.11%, respectively, for the quarter ended July 2019. Do the numbers hold clues to what lies ahead for the stock?
Teledyne Technologies, Netgear, Boston Scientific, Medtronic and Becton Dickinson highlighted as Zacks Bull and Bear of the Day
On its advisory list, the FDA suggests that doctors should point out the risks and benefits of all available PAD treatment options to their patients.
This study outcome is expected to be a major stride forward in Cardiovascular Systems' (CSII) endeavor to offer treatment to patients of multi-level peripheral artery disease (PAD).